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Abstract
Background: MicroRNA-21 (miR-21) is up-regulated in tumor tissue of patients with malignant diseases, including
hepatocellular carcinoma (HCC). Elevated concentrations of miR-21 have also been found in sera or plasma from patients
with malignancies, rendering it an interesting candidate as serum/plasma marker for malignancies. Here we correlated
serum miR-21 levels with clinical parameters in patients with different stages of chronic hepatitis C virus infection (CHC) and
CHC-associated HCC.
Methodology/Principal Findings: 62 CHC patients, 29 patients with CHC and HCC and 19 healthy controls were
prospectively enrolled. RNA was extracted from the sera and miR-21 as well as miR-16 levels were analyzed by quantitative
real-time PCR; miR-21 levels (normalized by miR-16) were correlated with standard liver parameters, histological grading and
staging of CHC. The data show that serum levels of miR-21 were elevated in patients with CHC compared to healthy
controls (P,0.001); there was no difference between serum miR-21 in patients with CHC and CHC-associated HCC. Serum
miR-21 levels correlated with histological activity index (HAI) in the liver (r=20.494, P=0.00002), alanine aminotransferase
(ALT) (r=20.309, P=0.007), aspartate aminotransferase (r=20.495, P=0.000007), bilirubin (r=20.362, P=0.002),
international normalized ratio (r=20.338, P=0.034) and c-glutamyltransferase (r=20.244, P=0.034). Multivariate analysis
revealed that ALT and miR-21 serum levels were independently associated with HAI. At a cut-off dCT of 1.96, miR-21
discriminated between minimal and mild-severe necroinflammation (AUC=0.758) with a sensitivity of 53.3% and a
specificity of 95.2%.
Conclusions/Significance: The serum miR-21 level is a marker for necroinflammatory activity, but does not differ between
patients with HCV and HCV-induced HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common
solid tumors, rated third in mortality worldwide [1]. Most HCCs
develop in fibrotic or already cirrhotic liver which are a result of
chronic infection with hepatitis B (HBV) or hepatitis C virus (HCV)
[1]. Currently, there are no biomarkers for the early detection of
HCC, and most patients with HCC are diagnosed at advanced
stages, which are associated with poor prognosis and low survival
rates due to a lack of curative treatment options. a-Fetoprotein
(AFP) has mainly been used for diagnosis of HCC; however, its
sensitivity and specificity are not satisfying [2].
MicroRNAs (miRNAs) are small noncoding RNAs (18–24
nucleotides) that interact with their target mRNAs to inhibit
translationbypromoting mRNAdegradationortoblocktranslation
by binding to complementary sequences in the 39-untranslated
region of mRNAs [3]. An integral role of miRNAs in cancer
pathogenesis has begun to emerge. MiRNA expression profiling
reveals characteristic signatures for many tumor types [4].
Importantly, miRNAs have also been detected in human serum
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possibility that unique miRNA patterns in serum and plasma might
be used as non-invasive disease markers. In support of this,
differences have been found between miRNA patterns in serum or
plasma of patients with a number of malignancies and healthy
controls [5].
Analysis of the miRNA signatures of a large number of tumor
samples, including lung, breast, stomach, prostate, colon, and
pancreatic cancer and their respective normal adjacent tissue,
revealed that miR-21 is the only miRNA upregulated in all these
tumors [4], including HCC [6–9]. Considerable evidence supports
the hypothesis that miR-21 is a central oncomiR [10]. miR-21
levels are also significantly elevated in serum/plasma of patients
with diffuse large B-cell lymphoma, ovarian cancer, prostate
cancer or breast cancer [11–13], rendering it an interesting
candidate as serum/plasma marker for malignancies.
miR-21 has also been linked to fibrosis in the lung [14], heart
[15] and liver [9]. In the liver the level of miR-21 correlates with
hepatic fibrosis [9]. A close link between miR-21 and hepatic
fibrosis is supported by the findings that transforming growth
factor b (TGF-b), a critical mediator of hepatic fibrogenesis
[16,17], promotes the expression of miR-21 [18], and that miR-21
decreases the expression of SMAD7 [9], a negative regulator of
TGF-b signalling [17]. A recent study has reported that circulating
miR-21 might be useful as biomarker for HCC [19].
Alterations of the miR-21 concentration in serum or plasma of
patients with HCV-induced chronic hepatitis C (CHC) have not
yet been reported. Hypothesizing that miR-21 serum levels might
be related to either malignancy, i. e. HCC, or liver fibrosis/
cirrhosis or both, we here investigated the relation between miR-
21 serum levels and clinical parameters in patients with CHC,
CHC plus HCC, and healthy volunteers.
Methods
Patients
Patients with CHC (n=62) as well as CHC plus HCC (n=29),
who had undergone liver biopsy for staging and grading of CHC at
the Frankfurt University hospital, were prospectively enrolled in the
present cohort study. An independent cohort of 47 CHC patients
Table 1. Characteristics of CHC patients, CHC patients with HCC and healthy subjects.
CHC patients (n=62) CHC patients with HCC (n=29) Healthy subjects (n=19)
Age (years) Mean 6 SD 46.1611.2 61.469.1 33.2610.6
Sex (n) Male 34 (54.8%) 22 (75.9%) 11 (57.9%)
Female 28 (45.2) 7 (24.1%) 8 (42.1%)
HAI (n) 2 7 (11.3%) -
3 8 (12.9%) -
4 13 (21.0%) -
5 10 (16.1%) 2 (6.9%)
6 14 (22.6%) 1 (3.4%)
7 5 (8.1%) 2 (6.9%)
8 2 (3.2%) 2 (6.9%)
9 3 (4.8%) 2 (6.9%)
11 - 1 (3.4%)
Unknown - 19 (65.5%)
Fibrosis (n) F0 7 (11.3%) -
F1 20 (32.3%) -
F2 4 (6.5%) -
F3 6 (9.7%) -
F4 10 (16.1%) 3 (10.3%)
F5 4 (6.5%) 1(3.4%)
F6 5 (8.1%) 9 (31.0%)
Unknown 6 (9.7%) 16 (55.2%)
ALT (n) Elevated* 44 (71.0%) 24 (82.8%)
Normal 18 (29.0%) 5 (17.2%)
*.35 IU/l female; .50 IU/l male.
doi:10.1371/journal.pone.0026971.t001
Table 2. Characteristics of the independent validation cohort
of CHC patients.
CHC patients
(n=47)
Age (years) Mean6SD 45.4610.4
Sex (n) Male 22 (46.8%)
Female 25 (53.2%)
ALT (n) Elevated* 34 (72.3%)
Normal 13 (27.7%)
*.35 IU/l female; .50 IU/l male.
doi:10.1371/journal.pone.0026971.t002
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antibodiesandHCV-RNAforat leastsixmonths.Exclusion criteria
were decompensated liver disease, malignancy other than HCC,
organ transplantation, co-infection with HIV or HBV, immuno-
suppression and autoimmune co-morbidities. Patients’ characteris-
tics are summarized in Table 1 and 2. The Ethics Committee of the
University Hospital Frankfurt approved this study. From all
enrolled patients and healthy subjects written informed consent
was obtained according to the Declaration of Helsinki.
Liver Histology
Hematoxylin-eosin stained sections of formalin-fixed, paraffin-
embedded liver biopsies were reviewed by experienced patholo-
gists for evaluation of fibrosis stages (F0=no fibrosis - F6=cir-
rhosis) and the histologic activity index (HAI) in the liver according
to the Ishak criteria [20].
Blood Sampling
10 mL of peripheral blood was collected at the time of liver
biopsy (serum tubes, Sarstedt, Nu ¨mbrecht, Germany). Cellular
components were removed by two consecutive centrifugation steps
(1500 g for 10 min at 4uC and 2000 g for 3 min at 4uC,
respectively). Sera were stored at 280uC until use.
Detection of miRNAs by Quantitative Real-time Reverse-
Transcription (RT)-PCR
RNA was isolated from 500 mL serum using TriHReagentLS
(Sigma-Aldrich, St. Louis, MO), chloroform and the mirVana
TM
RNA isolation kit (Ambion-ABI, Austin, TX). Total RNA was
eluted in 100 mL and stored at 220uC. 5 mL of RNA was reverse
transcribed with the TaqManH miRNA reverse transcription kit
and the TaqManH miRNA assay specific RT primers for miR-21
or miR-16 according to the instructions of the manufacturer (ABI).
Real-time PCR was performed with 3 mL of each cDNA on a
StepOne
TMPlus Real-Time PCR System (ABI) in duplicates. The
cycle treshold (CT) defines the number of PCR cycles required for
the fluorescent signal to cross the threshold.
Statistical Analysis
Data were analyzed using the BiAS software for windows
(version 9.07). Statistical significance for correlations was deter-
mined using Spearman’s nonparametric rank test. Differences
between two groups were evaluated using the Wilcoxon-Mann-
Whitney-U test. P values,0.05 were considered to be significant.
For the multivariate analysis a logistic regression with Wald’s test
was used to evaluate whether minimal (HAIA+B+C#3) vs. mild to
severe (HAIA+B+C.3) necroinflammation correlated independent-
ly with the parameters. The criterion for elimination in the
stepwise model was P.0.1.
Figure 1. Increased serum miR-21 concentrations in patients
with CHC and elevated levels of ALT. (A), dCT values of miR-21 of
sera from healthy control individuals (n=19), patients with CHC and
elevated serum ALT levels (n=44) and CHC patients with normal serum
ALT levels (n=18). Boxes represent range, median and quartiles of the
number of threshold cycles (CT) required to detect miR-21 by real-time
RT-qPCR normalized to CT of miR-16. Differences were calculated with
Wilcoxon-Mann-Whitney-U-test. *P,.05, ***P,.001, compared with the
healthy control group.
+++P,.001 between CHC patients with normal or
elevated ALT. (B), ROC curve analysis of serum miR-21 concentration for
discriminating CHC patients and healthy controls. (C), dCT values of CHC
patients with elevated ALT and HAI$5 (n=31) and patients with CHC
and HCC (n=29) showing no significant difference in miR-21 levels
(Wilcoxon-Mann-Whitney-U-test: P..3) between both groups, n. s.=not
significant. (D) Relationship between serum miR-21 levels and the
serum HCV RNA in patients with CHC. The relation is not significant
(P=.29).
doi:10.1371/journal.pone.0026971.g001
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miR-21 as well as miR-16, a miRNA found at constant levels in
sera from various diseases, including chronic hepatitis B [5,13],
were quantified by real-time RT-PCR in sera from patients with
CHC, CHC plus HCC and healthy controls. The mean CT values
(95% confidence interval (CI)) of miR-16 were 25.1 (24.5–25.6) in
healthy donors and 25.2 (24.9–25.5), 25.0 (24.4–25.6) and 25.1
(24.2–26.0) in patients with CHC, in patients with CHC and
normal alanine aminotransferase (ALT) and CHC plus HCC,
respectively, showing that miR-16 in serum can be used as an
internal control to normalize sampling variations in RT-qPCR in
our collective of sera. The dCT (CT-miR-21 - CT-miR-16) value
negatively correlates with the serum level of miR-21. dCT of miR-
21 was higher in sera from healthy controls (3.4, CI: 3.0–3.8) than
in sera from patients with CHC and elevated serum ALT activity
(2.2, CI: 2.0–2.4) (P,0.001, Fig. 1A), a parameter reflecting liver
damage. In contrast, the dCT value for miR-21 in sera from CHC
patients with normal ALT values (3.0, CI: 2.7–3.3, P,0.05) only
slightly differed from that of the control sera (Fig. 1A). ROC curve
analysis was performed on the data from all CHC patients
(without HCC) and controls. The area under the ROC curve
(AUC) was 0.826 (CI: 0.711–0.942) (Fig. 1B), with a P value of
0.000018. The optimal cut-off value for miR-21 (normalized to
miR-16) to discriminate between healthy controls and CHC
patients was 3.16, with a sensitivity of 87.1%, specificity of 73.7%
and false classification rate of 19.6%.
There was no significant difference between the dCT values of
miR-21 in sera from patients with CHC plus HCC and those with
CHC and matched HAI (Fig. 1C). Moreover, we investigated if
Figure 3. Correlation between serum miR-21 levels and ALT (A)
or AST (B) in patients with CHC. Points represent dCT values for
miR-21 normalized to miR-16.
doi:10.1371/journal.pone.0026971.g003
Figure 2. Relationship between serum miR-21 levels and INR
(A), bilirubin (B), c-GT (C) and serum albumin concentration
(D).
doi:10.1371/journal.pone.0026971.g002
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HCV RNA. However, there was no correlation between the
serum miR-21 and HCV RNA level (P=0.29) (Fig. 1D).
To investigate the relation between the serum miR-21 level and
standard liver function parameters, we correlated the relationship
between the levels of miR-21 with the serum albumin concentra-
tion, international normalized ratio (INR), bilirubin and c-
glutamyl-transferase (c-GT). There were positive correlations
between the serum level of miR-21 and INR (r=20.362,
P=0.002) (Fig. 2A), serum bilirubin concentration (r=20.338,
P=0.003) (Fig. 2B) and c-GT activity (r=20.244, P=0.034)
(Fig. 2C). The correlation between the serum albumin concentra-
tion and the serum miR-21 level did not reach statistical
significance (P=0.0893) (Fig. 2D).
To examine if the levels of miR-21 in sera from patients with
CHC as well as CHC plus HCC reflects necroinflammatory
activity in the liver rather than HCC, we correlated the dCT
values of serum miR-21 with ALT, aspartate aminotransferase
(AST) as well as with the histologic activity index (HAI) score in
the liver. The dCT value of miR-21 in the sera negatively
correlated with serum levels of ALT (r=20.309, P=0.007)
(Fig. 3A) and AST (r=20.495, P=0.000007) (Fig. 3B), i. e. the
serum level of miR-21 positively correlated with ALT and AST
activities. The dCT values of serum miR-21 also strongly
correlated with the HAI score (r=20.494, P=0.00002) (Fig. 4A).
In order to confirm the correlation between serum miR-21 levels
and hepatic necroinflammation, we examined an independent
validation cohort of 47 CHC patients. As illustrated in Fig. 5, the
serum levels of miR-21 correlated with ALT (r=20.352,
P=0.015588) and AST (r=20.375, P=0.010614). Histological
classification according to Ishak was not available for these patients.
To investigate if the serum miR-21 level might be useful to
discriminate patients with minimal (HAIA+B+C#3) and mild to
severe necroinflammation in the liver (HAIA+B+C.3), we per-
formed multivariate analysis to examine the independency of the
different parameters. Multivariate analysis revealed that only the
correlations between HAI and serum ALT as well as miR-21 were
independent (Table 3).
To test the suitability of miR-21 to discriminate minimal from
mild to severe necroinflammation, we performed a ROC curve
Figure 5. Validation of the relationship between the serum
levels of miR-21 and ALT (A) and AST (B) in an independent
cohort of 47 CHC patients.
doi:10.1371/journal.pone.0026971.g005
Figure 4. Relationship between serum miR-21 levels and the
HAI score (A); (B), ROC curve analysis of serum miR-21 concentration
for discriminating patients with minimal (HAIA+B+C#3) vs. moderate to
severe necroinflammatory activity (HAIA+B+C.3) using dCT of miR-21;
(C), relationship between serum miR-21 and fibrosis index in patients
with CHC.
doi:10.1371/journal.pone.0026971.g004
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At the optimal cut-off value of 1.96, the sensitivity was 53.3%, the
specificity 95.2% and false classification rate was 25.7%.
To investigate if the serum miR-21 level might be related to
liver fibrosis, we correlated the dCT values of serum miR-21 and
the histological fibrosis index in the liver. There was a trend
towards a negative correlation between the Ishak fibrosis index
and the dCT of miR-21 in the sera from CHC patients
(r=20.243, P=0.054) (Fig. 4C).
Discussion
Compared to the corresponding normal tissue miR-21 has been
shown to be consistently elevated in malignant tumors, including
HCC [4,7]. Importantly, this miRNA is not only upregulated in
association with oncogenesis, but can act as oncogenic miRNA
[21]. It inhibits targets related to apoptosis and to transformation
such as programmed cell death 4 and phosphatase and tensin
homolog [6,22]. miR-21 is also elevated in sera from patients with
prostate carcinoma [12], mamma carcinoma [13,22] and HBV-
associated HCC [23], raising the possibility that it may serve as
serum marker for malignant diseases. A recent study has suggested
that circulating miR-21 is a marker for HCC [19]. However, that
study did not allow differentiation between patients with liver
cirrhosis and HCC. We report here that the level of miR-21 in
sera from patients with CHC-associated HCC was elevated
compared to healthy controls. However, we also detected
increased levels of miR-21 in sera from patients with CHC
without HCC. Indeed, sera from patients with matched HAI score
and CHC showed similar miR-21 levels than sera from patients
with CHC-associated HCC. Thus, the elevation of serum miR-21
levels in our CHC patients appears to be mainly associated with
chronic hepatitis rather than HCC. The link between the elevated
levels of serum miR-21 and CHC is supported by our finding that
miR-21 serum levels strongly correlated with ALT and AST
activities in two independent cohorts of CHC patients, parameters
of ongoing liver damage. Concordantly, elevated serum levels of
miR-21 were found only in CHC patients showing elevated ALT
levels, whereas sera from CHC patients with normal ALT levels
also contain normal miR-21 serum concentrations. Moreover, the
serum miR-21 levels also strongly correlated with the HAI score,
supporting the suggestion that the serum miR-21 level is related to
necroinflammatory activity in the liver in patients with CHC.
Multivariate analysis of the data from patients with minimal or
mild to severe necroinflammation in the liver revealed that only
ALT and miR-21 correlated independently with necroinflamma-
tion in the liver. Thus, the serum miR-21 concentration might be a
useful parameter to differentiate patients with minimal vs. mild to
severe necroinflammation in the liver which is of clinical
relevance.
Mechanistically, miR-21 may leak from damaged cells similar to
ALT and AST, or may be actively exported from altered tissues as
a mechanism of adaptation to alterations of the state of a cell [24].
Recent evidence suggests that the majority of miRNAs in serum or
plasma, including miR-21, is complexed to proteins such as Ago2,
thereby explaining the high stability of endogenous miRNAs in
serum/plasma [25].
There is clear evidence for a close relation between miR-21 and
hepatic fibrosis. Thus, the hepatic level of miR-21 appears to
correlate with the stage of liver fibrosis [9]. miR-21 is strongly
expressed in tumor cells, but also in tumor-associated fibroblasts
[26]. In the present study the miR-21 concentration in serum
showed a strong correlation with the HAI score, whereas the
relation between the serum miR-21 level and the fibrosis score did
not reach statistical significance, which is in agreement with a
study published during revision of the present manuscript [27].
This suggests that serum miR-21 levels are related to liver damage
activity rather than to liver fibrosis in patients with CHC.
There was no correlation between the concentrations of miR-21
and HCV RNA in serum. This can be reconciled with the lack of
correlation of HCV serum level and disease activity in patients
with CHC [28].
Similar to the data of the present study, it has recently been
reported that sera from HBV-induced chronic hepatitis contain
elevated levels of miR-21 in comparison to healthy controls [23].
However, in another study with patients suffering from HBV-
induced chronic hepatitis, no elevation of serum miR-21 levels was
found despite strongly elevated ALT and HAI scores in these
patients [29], leaving the role of serum miR-21 in HBV-induced
chronic hepatitis unclear.
Recent studies reported differential levels of miR-16 in sera
from patients with HCC, chronic hepatitis of different etiology and
healthy controls [27,30]. In the present study, however, we did not
find differences in the levels of miR-16 between sera from patients
with CHC, CHC-associated HCC and healthy controls. Our data
are in agreement with several other studies reporting invariant
levels of miR-16 in sera from patients with several diseases [13],
including HBV-induced chronic hepatitis and HCC, and healthy
Table 3. Uni- and multivariate analysis of factors correlated to minimal (HAI#3) vs. mild to severe (HAI.3) necroinflammation.
Univariate analysis Multivariate analysis
Odds ratio 95% confidence intervall Wald’s p-value Odds ratio 95% confidence intervall Wald’s p-value
Fibrosis stage 1.4821 1.1150–1.9701 0.006744
Sex 0.9524 0.3266–2.7774 0.928807
Age 1.0817 1.0203–1.1469 0.008421
Log bilirubin 1.7982 0.2684–12.0467 0.545413
Log ALT 17.5591 2.4437–126.1671 0.004399 17.5478 1.3734–224.2070 0.027520
Log AST 36.3935. 3.3857–391.2003 0.003012
Log cGT 2.4165 0.6476–9.0177 0.189115
INR 19.1873 0.2329–1580.7251 0.18933
miR21-16 0.1507 0.0399–0.5694 0.005262 0.1734 0.0487–0.6168 0.006804
The HAI score used for this analysis was the sum of HAI-A, -B and -C.
doi:10.1371/journal.pone.0026971.t003
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normalization [13]. The reasons for the different findings between
the studies remain elusive.
Our recent data show that serum levels of the liver-specific miR-
122 also correlate with the HAI score as well as serum AST and
ALT levels [31]. Thus, miR-21 and miR-122 may originate from
the inflamed liver. However, miR-21 and miR-122 differ in that
miR-21, but not miR-122, correlates with bilirubin, INR and c-
GT in CHC patients. Obviously, the serum levels of miR-21 and
miR-122 reflect overlapping, but not identical disease parameters
in CHC patients. This might be related to the different expression
pattern of miR-21 and miR-122, miR-122 being highly selective
for the liver, whereas miR-21 shows significant expression in other
cells and tissues. For instance, miR-21 is strongly expressed in
lymphocytes [32]. Thus, release of miR-21 from several different
cell types may contribute to the elevation of the serum miR-21
level in patients with chronic hepatitis. A drawback of the broader
expression pattern of miR-21 compared to miR-122 is that co-
morbidities are more likely to reduce the diagnostic power of the
serum miR-21 level than that of miR-122.
The identification of non-invasive biomarkers for the diagnosis
of diseases has become a rapidly growing area of clinical research
[33]. The discovery of miRNAs circulating in the peripheral blood
has opened new directions of research to identify new non-invasive
ways of diagnosis of disease. In summary, the data of the present
study indicate that the level of serum miR-21 is suitable to detect
necroinflammatory activity in the liver and not the presence of
HCC. It appears likely that serum miRNAs can provide
information on different aspects of chronic hepatitis not available
from the presently used routine parameters of liver damage.
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